ERS Genomics announces agreement with New England Biolabs® to commercialize CRISPR gene editing tools and reagents
License agreement expands New England Biolabs’ rights to use and sell CRISPR/Cas9 reagents and tools
DUBLIN, Ireland, and Ipswich MA, USA, (07 January 2020): ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with New England Biolabs (NEB®), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.
NEB offers the largest selection of recombinant and native enzymes for genomic research, and continues to expand its product offerings into new areas of research, including genome editing. As a provider of CRISPR/Cas9 reagents and tools, NEB’s license from ERS Genomics expands the Company’s rights to use and sell these technologies.
ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational IP covering CRISPR/Cas9. Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents and genetically modified cell lines and organisms.
“New England Biolabs is a recognized world leader in the discovery and production of enzymes for molecular biology applications,“ stated Eric Rhodes, CEO of ERS Genomics. “Adding CRISPR/Cas9 to the company’s portfolio ensures it can continue to support its customers in the latest areas of technology advancement. We are very pleased that NEB chose to license CRISPR/Cas9 technology through ERS Genomics."
“CRISPR/Cas9-based methods have democratized genome editing, enabling researchers across industry and academia ready access to this cutting edge technology,“ stated Breton Hornblower, Product Marketing Manager, RNA Biology and Genome Editing. “NEB is excited to provide researchers with reagents and workflows that broaden the available molecular toolbox and uphold our worldwide reputation as a provider of quality and value in research reagents.“
Financial details of the agreement are not disclosed.
For more information about CRISPR/Cas9 reagents available from New England Biolabs, visit www.neb.com/GenomeEditing
Media contact for ERS Genomics:
Tel: +44(0)7787 502 947
Email: [email protected]
Media contact for New England Biolabs:
Deana D. Martin, Ph.D.
Associate Director, Marketing Communications
New England Biolabs
Tel: +1 978-380-7464
Email: [email protected]
About ERS Genomics www.ersgenomics.com
ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com
About New England Biolabs www.neb.com
Established in the mid 1970’s, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, genome editing epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.
NEW ENGLAND BIOLABS® and NEB® are registered trademarks of New England Biolabs, Inc.